1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Prazepam Oral Drops
Trade Name: LYSANXIA; PRAZENE; CENTRAC; CENTRAX; DEMETRIN; MONODEMETRIN; REAPAM
Chemical Family: Benzodiazepine

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product used as antianxiety agent

Details of the Supplier of the Safety Data Sheet
Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture
GHS - Classification: Not classified as hazardous

EU Classification:
EU Indication of danger: Not classified

Label Elements
Signal Word: Not Classified
Hazard Statements: Non-hazardous in accordance with international standards for workplace safety.

Other Hazards
No data available

Australian Hazard Classification (NOHSC):

Note:
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous
LYȘANXIA
3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethyldiethylene glycol</td>
<td>111-90-0</td>
<td>203-919-7</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>L-Menthol</td>
<td>2216-51-5</td>
<td>218-690-9</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Prazepam</td>
<td>2955-38-6</td>
<td>220-975-8</td>
<td>Repr. Cat.3, R62-63</td>
<td>Lact. (H362)</td>
<td>1.5</td>
</tr>
</tbody>
</table>

Additional Information:
* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed
Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.
Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

<table>
<thead>
<tr>
<th>Measures for Cleaning / Collecting:</th>
<th>Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional Consideration for Large Spills:</td>
<td>Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.</td>
</tr>
</tbody>
</table>

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

<table>
<thead>
<tr>
<th>Storage Conditions:</th>
<th>Store as directed by product packaging.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specific end use(s):</td>
<td>Pharmaceutical drug product</td>
</tr>
</tbody>
</table>

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Ethyl diethylene glycol

<table>
<thead>
<tr>
<th>Austria OEL - MAKs</th>
<th>6 ppm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estonia OEL - TWA</td>
<td>10 ppm</td>
</tr>
<tr>
<td>Germany - TRGS 900 - TWAs</td>
<td>6 ppm</td>
</tr>
<tr>
<td>Germany (DFG) - MAK</td>
<td>35 mg/m³</td>
</tr>
<tr>
<td>Sweden OEL - TWAs</td>
<td>15 ppm</td>
</tr>
<tr>
<td>Switzerland OEL -TWAs</td>
<td>50 mg/m³</td>
</tr>
</tbody>
</table>

| Prazepam Pfizer OEL TWA-8 Hr: | 70µg/m³ |

Propylene glycol

<table>
<thead>
<tr>
<th>Australia TWA</th>
<th>150 ppm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>474 mg/m³</td>
</tr>
<tr>
<td></td>
<td>10 mg/m³</td>
</tr>
</tbody>
</table>
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical State:</td>
<td>Liquid</td>
</tr>
<tr>
<td>Odor:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Solvent Solubility:</td>
<td>No data available</td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>No data available</td>
</tr>
<tr>
<td>pH:</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting/Freezing Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition Coefficient: (Method, pH, Endpoint, Value)</td>
<td>No data available</td>
</tr>
<tr>
<td>Prazepam</td>
<td>No data available</td>
</tr>
<tr>
<td>Sodium saccharin</td>
<td>No data available</td>
</tr>
<tr>
<td>Ethyldiethylene glycol</td>
<td>No data available</td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>No data available</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>No data available</td>
</tr>
<tr>
<td>Patent Blue V</td>
<td>No data available</td>
</tr>
<tr>
<td>Anethole NF</td>
<td>No data available</td>
</tr>
<tr>
<td>L-Menthol</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition Temperature (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation Rate (Gram/s):</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor Pressure (kPa):</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor Density (g/ml):</td>
<td>No data available</td>
</tr>
</tbody>
</table>

LYSANXIA
10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
- Oxidizing Properties: No data available
- Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
- Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
- Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May cause eye irritation (based on components).
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver, male reproductive system, kidneys, ureter, bladder, immune system (based on components).
Known Clinical Effects: Therapeutic use of this substance has resulted in weakness, dizziness, drowsiness, ataxia, confusion, tremors, headache, and gastrointestinal disturbances. This material has been shown to be secreted in low concentrations in human breast milk. The following effects are based on a chemically-related material: symptoms of dependence/withdrawal, insomnia, amnesia, agitation, nightmares, hallucinations.

Acute Toxicity: (Species, Route, End Point, Dose)

**Prazepam**
- Mouse Oral LD50 2.3 g/kg
- Rat Oral LD50 >4g/kg
- Rat IP LD50 >2g/kg
- Mouse IP LD50 1g/kg

**Sodium saccharin**
- Mouse Oral LD50 17.5 g/kg
- Rat Oral LD50 14.2 - 17g/kg
- Rat Intraperitoneal LD50 7100mg/kg

**Ethyl diethylene glycol**
- Rat Oral LD50 1920 mg/kg
- Rabbit Dermal LD50 4200uL/kg

**Polysorbate 80**
11. TOXICOLOGICAL INFORMATION

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Propylene glycol
Skin Irritation Rabbit Mild
Eye Irritation Rabbit Mild

L-Menthol
Eye Irritation Rabbit Severe
Skin Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Prazepam
35 Day(s) Rat Oral 35 mg/kg LOAEL Liver, Male reproductive system
11 Week(s) Dog Oral 13.5 mg/kg/day NOAEL Liver
57 Week(s) Dog Oral 5 mg/kg/day LOAEL Liver, Nervous System

Sodium saccharin
36 Week(s) Rat Oral 756 g/kg LOAEL Kidney, Ureter, Bladder
54 Day(s) Rat Oral 32400 mg/kg LOAEL Immune system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Prazepam
Reproductive & Fertility Mouse Oral 0.02 % LOAEL Reproductive toxicity, Fetotoxicity
Reproductive & Fertility Rat No route specified 80 mg/kg LOAEL Reproductive toxicity, Fetotoxicity
Embryo / Fetal Development Rat Oral 250 mg/kg NOAEL Maternal Toxicity, Fetotoxicity, Embryotoxicity
Embryo / Fetal Development Rabbit Oral 12 mg/kg/day LOAEL Fetotoxicity, Embryotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)
Genetic Toxicity Comments: Genetic toxicity tests were negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Prazepam
2 Year(s) Rat Oral, in feed Not carcinogenic
2 Year(s) Mouse Oral, in feed Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below.

Prazepam
IARC: Group 3 (Not Classifiable)
SAFETY DATA SHEET

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been thoroughly investigated. Releases to the environment should be avoided. See aquatic toxicity data for individual components below:

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Ethylidihyethylene glycol
Oncorhynchus mykiss (Rainbow Trout)  OECD LC50 96 Hours 13,420 mg/L
Pimephales promelas (Fathead Minnow)  OECD LC50 96 Hours 26,400 mg/L
Lepomis macrochirus (Bluegill Sunfish)  OECD LC50 96 Hours 10,000 mg/L

L-Menthol
Pimephales promelas (Fathead Minnow) LC50 96 Hours 18.9 mg/L

Persistence and Degradability: No data available
Bio-accumulative Potential: No data available
Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
D2a very toxic materials

Anethole NF
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 203-205-5

Ethylenediethylene glycol
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 203-919-7

L-Menthol
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 218-690-9

Patent Blue V
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 204-934-1

Polysorbate 80
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List Not Listed

Prazepam
CERCLA/SARA 313 Emission reporting Not Listed
developmental toxicity initial date 10/1/92
15. REGULATORY INFORMATION

| U.S. Drug Enforcement Administration: | Schedule IV Controlled Substance |
| Australia (AICS): | Present |
| Standard for the Uniform Scheduling for Drugs and Poisons: | Schedule 4 |
| EU EINECS/ELINCS List | 220-975-8 |

Propylene glycol
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 200-338-0

Sodium saccharin
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 204-886-1

Additional Information: US DEA Schedule IV substance

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

- Reproductive toxicity-Cat.2; H361fd - Suspected of damaging fertility. Suspected of damaging the unborn child.
- Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children

- Toxic to Reproduction: Category 3
- R62 - Possible risk of impaired fertility.
- R63 - Possible risk of harm to the unborn child.
- R64 - May cause harm to breastfed babies.

Data Sources: Safety data sheets for individual ingredients. Publicly available toxicity information. Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 9 - Physical and Chemical Properties. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 16 - Other Information.

Revision date: 11-Sep-2014
Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet